UK markets close in 5 hours 6 minutes

Ipsen S.A. (IPSEF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
132.500.00 (0.00%)
At close: 04:00PM EDT
Full screen
Previous close0.00
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability rating
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • GlobeNewswire

    IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

    Aggregated presentation by day and by market Purchases of own shares from July 15th to 19th, 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 15/07/2024 FR0010259150 4 700 111,6159 XPAR IPSEN 549300M6SGDPB4Z94P11 15/07/2024 FR0010259150 1 140 111,5494 CEUX IPSEN 549300M6SGDPB4Z94P11 15/07/2024

  • GlobeNewswire

    IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

    Aggregated presentation by day and by market Purchases of own shares from July 8th to 12th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1108/07/2024FR00102591506 650111,0282XPARIPSEN549300M6SGDPB4Z94P1108/07/2024FR00102591502 700110,9397CEUXIPSEN549300M6SGDPB4Z94P1108/07/2024FR0010259150350111,1231TQ

  • GlobeNewswire

    Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

    Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potentialFS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified through the application of Foreseen’s proprietary proteomic platformsFS001 has demonstrated robust preclinical efficacy in multiple tumor models and exhibits a favorable preclinical safety profile PARIS, FRANCE, 11 Jul